Although several mGluR2/3 antagonists/NAMs show great therapeutic potential for the treatment of depression in preclinical investigations, the outcomes of clinical trials were not particularly encouraging (Umbricht et al. 2020). The gene discussed is GRM2; the disease is major depressive disorder.